메뉴 건너뛰기




Volumn 9, Issue 1, 2008, Pages 83-94

Management of acromegaly: Is there a role for primary medical therapy?

Author keywords

Acromegaly; Medical management; Pituitary tumor; Somatotroph adenoma

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LANREOTIDE SR; OCTREOTIDE; PEGVISOMANT; PLACEBO; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

EID: 39149090351     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-007-9061-1     Document Type: Review
Times cited : (27)

References (88)
  • 2
    • 33748652910 scopus 로고    scopus 로고
    • Drug Insight: Primary medical therapy of acromegaly
    • Katznelson L. Drug Insight: primary medical therapy of acromegaly. Nat Clin Pract Endocrinol Metab 2006;2:109-17.
    • (2006) Nat Clin Pract Endocrinol Metab , vol.2 , pp. 109-117
    • Katznelson, L.1
  • 3
    • 1442326975 scopus 로고    scopus 로고
    • Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
    • 1
    • Colao A, Ferone D, Marzullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr Rev 2004;25(1):102-52.
    • (2004) Endocr Rev , vol.25 , pp. 102-152
    • Colao, A.1    Ferone, D.2    Marzullo, P.3    Lombardi, G.4
  • 4
    • 0025700486 scopus 로고
    • Acromegaly
    • 14
    • Melmed S. Acromegaly. N Engl J Med 1990;322(14):941-1012.
    • (1990) N Engl J Med , vol.322 , pp. 941-1012
    • Melmed, S.1
  • 6
    • 0029826419 scopus 로고    scopus 로고
    • Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
    • 4
    • Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45(4):407-13.
    • (1996) Clin Endocrinol , vol.45 , pp. 407-413
    • Sheaves, R.1    Jenkins, P.2    Blackburn, P.3    Huneidi, A.H.4    Afshar, F.5    Medbak, S.6
  • 7
    • 0023929086 scopus 로고
    • Arthropathy in acromegalic patients before and after treatment: A long-term follow-up study
    • 5
    • Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol 1988;28(5):515-24.
    • (1988) Clin Endocrinol , vol.28 , pp. 515-524
    • Dons, R.F.1    Rosselet, P.2    Pastakia, B.3    Doppman, J.4    Gorden, P.5
  • 9
    • 0026004767 scopus 로고
    • Sleep apnea and systemic hypertension: A causal association review
    • 2
    • Hoffstein V, Chan CK, Slutsky AS. Sleep apnea and systemic hypertension: A causal association review. Am J Med 1991;91(2):190-6.
    • (1991) Am J Med , vol.91 , pp. 190-196
    • Hoffstein, V.1    Chan, C.K.2    Slutsky, A.S.3
  • 11
    • 0028829472 scopus 로고
    • Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
    • 12
    • Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80(12):3395-402.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 3395-3402
    • Melmed, S.1    Ho, K.2    Klibanski, A.3    Reichlin, S.4    Thorner, M.5
  • 12
    • 0025991116 scopus 로고
    • Plasma concentrations of atrial natriuretic hormone in acromegaly: Relationship to hypertension
    • 3
    • Soszynski P, Slowinska-Srzednicka J, Zgliczynski S. Plasma concentrations of atrial natriuretic hormone in acromegaly: relationship to hypertension. Acta Endocrinol (Copenh) 1991;125(3):268-72.
    • (1991) Acta Endocrinol (Copenh) , vol.125 , pp. 268-272
    • Soszynski, P.1    Slowinska-Srzednicka, J.2    Zgliczynski, S.3
  • 13
    • 0018747016 scopus 로고
    • Abnormal plasma catecholamine responses in acromegalics
    • 5
    • Van Loon GR. Abnormal plasma catecholamine responses in acromegalics. J Clin Endocrinol Metab 1979;48(5):784-9.
    • (1979) J Clin Endocrinol Metab , vol.48 , pp. 784-789
    • Van Loon, G.R.1
  • 14
    • 0029964803 scopus 로고    scopus 로고
    • Growth hormone, the insulin-like growth factor system, and the kidney
    • 5
    • Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996;17(5):423-80.
    • (1996) Endocr Rev , vol.17 , pp. 423-480
    • Feld, S.1    Hirschberg, R.2
  • 15
    • 0038173653 scopus 로고    scopus 로고
    • Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects
    • 2-3
    • Moller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 2003;13(2-3):55-74.
    • (2003) Growth Horm IGF Res , vol.13 , pp. 55-74
    • Moller, J.1
  • 18
    • 0035470209 scopus 로고    scopus 로고
    • Pathogenesis and prevalence of hypertension in acromegaly
    • 4
    • Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4(4):239-49.
    • (2001) Pituitary , vol.4 , pp. 239-249
    • Bondanelli, M.1    Ambrosio, M.R.2    Degli Uberti, E.C.3
  • 19
    • 0027300715 scopus 로고
    • An audit of outcome of treatment in acromegaly
    • 5
    • Bates AS, Hoff WV, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. QJM 1993;86(5):293-9.
    • (1993) QJM , vol.86 , pp. 293-299
    • Bates, A.S.1    Hoff, W.V.2    Jones, J.M.3    Clayton, R.N.4
  • 23
    • 0035404392 scopus 로고    scopus 로고
    • Clinical perspective: Acromegaly and cancer: Not a problem
    • 7
    • Melmed S. Clinical perspective: acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86(7):2929-34.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 2929-2934
    • Melmed, S.1
  • 26
    • 0031772696 scopus 로고    scopus 로고
    • Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
    • 10
    • Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83(10):3411-8.
    • (1998) J Clin Endocrinol Metab , vol.83 , pp. 3411-3418
    • Abosch, A.1    Tyrrell, J.B.2    Lamborn, K.R.3    Hannegan, L.T.4    Applebury, C.B.5    Wilson, C.B.6
  • 27
    • 0028817158 scopus 로고
    • Does treatment of acromegaly affect life expectancy
    • 11
    • Bates A. Does treatment of acromegaly affect life expectancy. Metabolism 1995;44(11):1-5.
    • (1995) Metabolism , vol.44 , pp. 1-5
    • Bates, A.1
  • 29
    • 0242351840 scopus 로고    scopus 로고
    • Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: Mortality, morbidity, and the effects of hospital and surgeon volume
    • 10
    • Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88(10):4709-19.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 4709-4719
    • Barker II, F.G.1    Klibanski, A.2    Swearingen, B.3
  • 30
    • 15944401695 scopus 로고    scopus 로고
    • The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
    • 3
    • Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005;152(3):379-87.
    • (2005) Eur J Endocrinol , vol.152 , pp. 379-387
    • Nomikos, P.1    Buchfelder, M.2    Fahlbusch, R.3
  • 31
    • 0034857211 scopus 로고    scopus 로고
    • Surgical management of GH-Secreting pituitary adenomas: An outcome study using modern remission criteria
    • 9
    • Kreutzer J, Vance ML, Lopes MBS, Laws ER Jr. Surgical management of GH-Secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86(9):4072-7.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 4072-4077
    • Kreutzer, J.1    Vance, M.L.2    Lopes, M.B.S.3    Laws Jr., E.R.4
  • 32
    • 0032909272 scopus 로고    scopus 로고
    • How many surgeons to operate on acromegalic patients
    • 5
    • Clayton. How many surgeons to operate on acromegalic patients. Clin Endocrinol 1999;50(5):557-9.
    • (1999) Clin Endocrinol , vol.50 , pp. 557-559
    • Clayton1
  • 34
    • 0030884349 scopus 로고    scopus 로고
    • Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor i in patients with acromegaly
    • 10
    • Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor i in patients with acromegaly. J Clin Endocrinol Metab 1997;82(10):3187-91.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 3187-3191
    • Barkan, A.L.1    Halasz, I.2    Dornfeld, K.J.3    Jaffe, C.A.4    Friberg, R.D.5    Chandler, W.F.6
  • 35
    • 0034458010 scopus 로고    scopus 로고
    • Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly
    • 7
    • Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85(7):2476-82.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2476-2482
    • Biermasz, N.R.1    Van Dulken, H.2    Roelfsema, F.3
  • 36
    • 0034455933 scopus 로고    scopus 로고
    • Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure
    • 5
    • Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000;85(5):2068-71.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2068-2071
    • Powell, J.S.1    Wardlaw, S.L.2    Post, K.D.3    Freda, P.U.4
  • 37
    • 0031812096 scopus 로고    scopus 로고
    • Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
    • 6
    • Landolt A, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998;88(6):1002-8.
    • (1998) J Neurosurg , vol.88 , pp. 1002-1008
    • Landolt, A.1    Haller, D.2    Lomax, N.3    Scheib, S.4    Schubiger, O.5    Siegfried, J.6
  • 38
    • 23844500632 scopus 로고    scopus 로고
    • Outcome of gamma knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion
    • 8
    • Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90(8):4483-8.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 4483-4488
    • Castinetti, F.1    Taieb, D.2    Kuhn, J.M.3    Chanson, P.4    Tamura, M.5    Jaquet, P.6
  • 39
    • 15944427116 scopus 로고    scopus 로고
    • The antitumoral effects of somatostatin analog therapy in acromegaly
    • 3
    • Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856-63.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 1856-1863
    • Bevan, J.S.1
  • 40
    • 0033729273 scopus 로고    scopus 로고
    • Signal transduction of somatostatin receptors negatively controlling cell proliferation
    • Ferjoux G, Bousquet C, Cordelier P, Bali NL, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000;94:205-10.
    • (2000) J Physiol Paris , vol.94 , pp. 205-210
    • Ferjoux, G.1    Bousquet, C.2    Cordelier, P.3    Bali, N.L.4
  • 41
    • 0028929754 scopus 로고
    • Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
    • 5
    • Buscail L, Esteve J, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Nat Acad Sci USA 1995;92(5):1580-4.
    • (1995) Proc Nat Acad Sci USA , vol.92 , pp. 1580-1584
    • Buscail, L.1    Esteve, J.2    Saint-Laurent, N.3    Bertrand, V.4    Reisine, T.5    O'Carroll, A.6
  • 44
    • 0036380541 scopus 로고    scopus 로고
    • Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma
    • 4
    • Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002;659(4):200-6.
    • (2002) Digestion , vol.659 , pp. 200-206
    • Koizumi, M.1    Onda, M.2    Tanaka, N.3    Seya, T.4    Yamada, T.5    Takahashi, Y.6
  • 45
    • 0024317498 scopus 로고
    • Octreotide. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion
    • 5
    • Battershill P, Clissold S. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38(5):658-702.
    • (1989) Drugs , vol.38 , pp. 658-702
    • Battershill, P.1    Clissold, S.2
  • 46
    • 10444279988 scopus 로고    scopus 로고
    • Sandostatin(R) LAR(R): A promising therapeutic tool in the management of acromegalic patients
    • Supplement 1
    • Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin(R) LAR(R): A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45 Supplement 1:67-71.
    • (1996) Metabolism , vol.45 , pp. 67-71
    • Lancranjan, I.1    Bruns, C.2    Grass, P.3    Jaquet, P.4    Jervell, J.5    Kendall-Taylor, P.6
  • 47
    • 4143066821 scopus 로고    scopus 로고
    • Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status
    • 2
    • Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 2004;61(2):209-15.
    • (2004) Clin Endocrinol , vol.61 , pp. 209-215
    • Cozzi, R.1    Attanasio, R.2    Lodrini, S.3    Lasio, G.4
  • 48
    • 0036111856 scopus 로고    scopus 로고
    • SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    • 5
    • Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16.
    • (2002) Eur J Endocrinol , vol.146 , pp. 707-716
    • Bruns, C.1    Lewis, I.2    Briner, U.3    Meno-Tetang, G.4    Weckbecker, G.5
  • 49
    • 0032730198 scopus 로고    scopus 로고
    • Long-acting formulations of somatostatin analogues
    • Suppl 2
    • Anthony L. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S216-8.
    • (1999) Ital J Gastroenterol Hepatol , vol.31
    • Anthony, L.1
  • 50
    • 0036513129 scopus 로고    scopus 로고
    • Somatuline Autogel: An extended release lanreotide formulation
    • 3
    • Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002;63(3):162-5.
    • (2002) Hosp Med , vol.63 , pp. 162-165
    • Lightman, S.1
  • 51
    • 0034974291 scopus 로고    scopus 로고
    • Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
    • 6
    • Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-86.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 2779-2786
    • Colao, A.1    Ferone, D.2    Marzullo, P.3    Cappabianca, P.4    Cirillo, S.5    Boerlin, V.6
  • 53
    • 0036153570 scopus 로고    scopus 로고
    • Long-term effects of lanreotide SR and octreotide LARR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
    • 1
    • Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LARR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002;56(1):65-71.
    • (2002) Clin Endocrinol , vol.56 , pp. 65-71
    • Amato, G.1    Mazziotti, G.2    Rotondi, M.3    Iorio, S.4    Doga, M.5    Sorvillo, F.6
  • 54
    • 0037381257 scopus 로고    scopus 로고
    • Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage
    • 4
    • Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol 2003;58(4):471-81.
    • (2003) Clin Endocrinol , vol.58 , pp. 471-481
    • Lucas, T.1    Astorga, R.2    Catala, M.3
  • 55
    • 17144431786 scopus 로고    scopus 로고
    • Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)
    • Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exper Clin Endocrinol Diabetes 2005;3:139-44.
    • (2005) Exper Clin Endocrinol Diabetes , vol.3 , pp. 139-144
    • Gutt, B.1    Bidlingmaier, M.2    Kretschmar, K.3    Dieterle, C.4    Steffin, B.5    Schopohl, J.6
  • 56
    • 0036148030 scopus 로고    scopus 로고
    • Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly
    • Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 99-104
    • Caron, P.1    Beckers, A.2    Cullen, D.R.3    Goth, M.I.4    Gutt, B.5    Laurberg, P.6
  • 57
    • 2342485029 scopus 로고    scopus 로고
    • Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
    • 4
    • van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150(4):489-95.
    • (2004) Eur J Endocrinol , vol.150 , pp. 489-495
    • Van Thiel, S.W.1    Romijn, J.A.2    Biermasz, N.R.3    Ballieux, B.E.4    Frolich, M.5    Smit, J.W.6
  • 58
    • 4744375607 scopus 로고    scopus 로고
    • Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR
    • 3
    • Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317-24.
    • (2004) Eur J Endocrinol , vol.151 , pp. 317-324
    • Alexopoulou, O.1    Abrams, P.2    Verhelst, J.3    Poppe, K.4    Velkeniers, B.5    Abs, R.6
  • 59
    • 21044441388 scopus 로고    scopus 로고
    • Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
    • 7
    • Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45(7):836-44.
    • (2005) J Clin Pharmacol , vol.45 , pp. 836-844
    • Astruc, B.1    Marbach, P.2    Bouterfa, H.3    Denot, C.4    Safari, M.5    Vitaliti, A.6
  • 60
    • 33845491265 scopus 로고    scopus 로고
    • Acromegaly
    • 24
    • Melmed S. Acromegaly. N Engl J Med 2006;355(24):2558-73.
    • (2006) N Engl J Med , vol.355 , pp. 2558-2573
    • Melmed, S.1
  • 62
    • 33745236035 scopus 로고    scopus 로고
    • Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal
    • 1
    • Livadas S, Hadjidakis J, Argyropoulou M, Stamatelatou M, Kelekis D, Raptis S. Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens) 2006 2007;5(1):57-63.
    • (2007) Hormones (Athens) 2006 , vol.5 , pp. 57-63
    • Livadas, S.1    Hadjidakis, J.2    Argyropoulou, M.3    Stamatelatou, M.4    Kelekis, D.5    Raptis, S.6
  • 67
    • 0026328373 scopus 로고
    • Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly
    • 11
    • Plockinger O, Quabbe H. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly. J Endocrinol Invest 1991;14(11):943-8.
    • (1991) J Endocrinol Invest , vol.14 , pp. 943-948
    • Plockinger, O.1    Quabbe, H.2
  • 68
    • 0016172045 scopus 로고
    • Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration
    • 5
    • Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974;38(5):910-2.
    • (1974) J Clin Endocrinol Metab , vol.38 , pp. 910-912
    • Liuzzi, A.1    Chiodini, P.G.2    Botalla, L.3    Cremascoli, G.4    Muller, E.E.5    Silvestrini, F.6
  • 70
    • 0019509233 scopus 로고
    • Bromocriptine therapy in acromegaly. a long-term review of 35 cases
    • 666
    • Sachdev Y, Gopal K, Garg VK. Bromocriptine therapy in acromegaly. A long-term review of 35 cases. Postgrad Med J 1981;57(666):210-6.
    • (1981) Postgrad Med J , vol.57 , pp. 210-216
    • Sachdev, Y.1    Gopal, K.2    Garg, V.K.3
  • 71
    • 0026701677 scopus 로고
    • Treatment of acromegaly with dopamine agonists
    • 3
    • Jaffe C, Barkan A. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21(3):713-35.
    • (1992) Endocrinol Metab Clin North Am , vol.21 , pp. 713-735
    • Jaffe, C.1    Barkan, A.2
  • 73
    • 0021276136 scopus 로고
    • Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests
    • May (5)
    • Nortier J, Croughs R, Thijssen J, Schwarz F. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests. Clin Endocrinol 1984;20 May (5):565-71.
    • (1984) Clin Endocrinol , vol.20 , pp. 565-571
    • Nortier, J.1    Croughs, R.2    Thijssen, J.3    Schwarz, F.4
  • 74
    • 0019471258 scopus 로고
    • Treatment results in 235 patients with acromegaly. a report of the acromegaly study group
    • Suppl
    • Quabbe H. Treatment results in 235 patients with acromegaly. A report of the acromegaly study group. Acta Endocrinol (Copenh). 1981;240 Suppl:66.
    • (1981) Acta Endocrinol (Copenh). , vol.240 , pp. 66
    • Quabbe, H.1
  • 75
    • 33749865531 scopus 로고    scopus 로고
    • Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study
    • 7
    • Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology 2006;67(7):1225-9.
    • (2006) Neurology , vol.67 , pp. 1225-1229
    • Yamamoto, M.1    Uesugi, T.2    Nakayama, T.3
  • 76
    • 0025322555 scopus 로고
    • Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
    • 13
    • Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 1990;87(13):5061-5.
    • (1990) Proc Natl Acad Sci USA , vol.87 , pp. 5061-5065
    • Chen, W.Y.1    Wight, D.C.2    Wagner, T.E.3    Kopchick, J.J.4
  • 77
  • 79
  • 80
    • 18744389775 scopus 로고    scopus 로고
    • Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
    • 9471
    • Feenstra J, de Herder WW, ten Have SMTH, van den Beld AW, Feelders RA, Janssen JAMJ, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet 2005;365(9471):1644-6.
    • (2005) The Lancet , vol.365 , pp. 1644-1646
    • Feenstra, J.1    De Herder, W.W.2    Have Smth, T.3    Van Den Beld, A.W.4    Feelders, R.A.5    Jamj, J.6
  • 81
    • 33847700931 scopus 로고    scopus 로고
    • Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
    • 1
    • Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156(1):75-82.
    • (2007) Eur J Endocrinol , vol.156 , pp. 75-82
    • Schreiber, I.1    Buchfelder, M.2    Droste, M.3    Forssmann, K.4    Mann, K.5    Saller, B.6
  • 84
    • 17644382943 scopus 로고    scopus 로고
    • GH Receptor antagonist: Mechanism of action and clinical utility
    • 1
    • Surya S, Barkan A. GH Receptor antagonist: mechanism of action and clinical utility. Rev Endoc Metab Disord 2005;6(1):5-13.
    • (2005) Rev Endoc Metab Disord , vol.6 , pp. 5-13
    • Surya, S.1    Barkan, A.2
  • 85
    • 0242572132 scopus 로고    scopus 로고
    • Dimerization of G-protein-coupled receptors: Roles in signal transduction
    • 2
    • Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 2004;16(2):175-86.
    • (2004) Cell Signal , vol.16 , pp. 175-186
    • Bai, M.1
  • 86
    • 14644387575 scopus 로고    scopus 로고
    • Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation
    • 3
    • Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005;26(3):131-7.
    • (2005) Trends Pharmacol Sci , vol.26 , pp. 131-137
    • Bulenger, S.1    Marullo, S.2    Bouvier, M.3
  • 88
    • 0034616021 scopus 로고    scopus 로고
    • Receptors for dopamine and somatostatin: Formation of Hetero-Oligomers with enhanced functional activity
    • 5463
    • Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of Hetero-Oligomers with enhanced functional activity. Science 2000;288(5463):154-7.
    • (2000) Science , vol.288 , pp. 154-157
    • Rocheville, M.1    Lange, D.C.2    Kumar, U.3    Patel, S.C.4    Patel, R.C.5    Patel, Y.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.